


## BI-3812

Cat. No.:	HY-111381		
CAS No.:	2166387-64-8		
Molecular Formula:	C <sub>26</sub> H <sub>32</sub> ClN <sub>7</sub> O <sub>5</sub>		
Molecular Weight:	558.03		
Target:	Bcl-2 Family		
Pathway:	Apoptosis		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 20.83 mg/mL (37.33 mM; Need ultrasonic)			
		Solvent Concentration	Mass	
			1 mg	5 mg
			10 mg	
	Preparing Stock Solutions	1 mM	5 mM	10 mM
		1.7920 mL	8.9601 mL	17.9202 mL
		0.3584 mL	1.7920 mL	3.5840 mL
		0.1792 mL	0.8960 mL	1.7920 mL
Please refer to the solubility information to select the appropriate solvent.				
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: 2.08 mg/mL (3.73 mM); Suspended solution; Need ultrasonic			
	2. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.08 mg/mL (3.73 mM); Clear solution			

### BIOLOGICAL ACTIVITY

Description	BI-3812 is potent and efficacious BCL6 inhibitor, inhibiting the BTB domain of BCL6, with an IC <sub>50</sub> of ≤3 nM; BI-3812 has antitumor activity.
IC <sub>50</sub> & Target	IC <sub>50</sub> : ≤3 nM (BCL6 BTB) <sup>[1]</sup>
In Vivo	BI-3812 is a BCL6 inhibitor, with an IC <sub>50</sub> of ≤3 nM. BI-3812 shows an IC <sub>50</sub> of 40 nM for the cellular BCL6 <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

---

## REFERENCES

---

[1]. Kerres N, et al. Chemically Induced Degradation of the Oncogenic Transcription Factor BCL6. Cell Rep. 2017 Sep 19;20(12):2860-2875.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA